AMG 420 Immunotherapy Shows Promise in Relapsed or Refractory Multiple Myeloma
Results from the first in-human clinical trial assessing Amgen’s…
Myeloma
Myeloma overview
Myeloma is a rare blood cancer that begins in plasma cells, a type of white blood cell normally responsible for producing antibodies that help fight off infectious pathogens and other threats.
Read moreMyeloma treatment
While myeloma treatment can drive the disease into remission, sometimes for long periods of time, the cancer will often come back after a few months or years, and additional treatments will be needed.
Read moreLatest news
Researchers Identify 3 Genetic Alterations Associated with Higher Risk of Myeloma in African-Americans
Researchers have identified three genetic alterations associated with the…
Seattle Genetics Initiates Phase 1 Trial of SEA-BCMA in Relapsed or Refractory Multiple Myeloma Patients
Seattle Genetics is recruiting patients with relapsed or…
Darzalex Extends Time to Disease Progression, Death Among Newly Diagnosed Multiple Myeloma Patients, Phase 3 Trial Shows
Multiple myeloma patients who are not eligible for high-dose chemotherapy…
Excessive RNA Editing Linked to Myeloma Progression, Treatment Resistance, Study Suggests
Abnormally high production of an RNA editing enzyme called…
FDA Grants Poseida’s P-BCMA-101 RMAT Status for Treatment of Multiple Myeloma
The U.S. Food and Drug Administration (FDA) …
